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Summary
Background Patients with advanced oesophageal cancer have a median survival of 3–6 months, and most require 
intervention for dysphagia. Self-expanding metal stent (SEMS) insertion is the most typical form of palliation in these 
patients, but dysphagia deterioration and re-intervention are common. This study examined the efficacy of adjuvant 
external beam radiotherapy (EBRT) compared with usual care alone in preventing dysphagia deterioration and 
reducing service use after SEMS insertion.
Methods This was a multicentre, open-label, phase 3 randomised controlled trial based at cancer centres and acute 
care hospitals in England, Scotland, and Wales. Patients (aged ≥16 years) with incurable oesophageal carcinoma 
receiving stent insertion for primary management of dysphagia were randomly assigned (1:1) to receive usual care 
alone or EBRT (20 Gy in five fractions or 30 Gy in ten fractions) plus usual care after stent insertion. Usual care was 
implemented according to need as identified by the local multidisciplinary team (MDT). Randomisation was via the 
method of minimisation stratified by treating centre, stage at diagnosis (I–III vs IV), histology (squamous or non-
squamous), and MDT intent to give chemotherapy (yes vs no). The primary outcome was difference in proportions 
of participants with dysphagia deterioration (>11 point decrease on patient-reported European Organisation for 
Research and Treatment of Cancer quality of life questionnaire-oesophagogastric module [QLQ-OG25], or a 
dysphagia-related event consistent with such a deterioration) or death by 12 weeks in a modified intention-to-treat 
(ITT) population, which excluded patients who did not have a stent inserted and those without a baseline QLQ-OG25 
assessment. Secondary outcomes included survival, quality of life (QoL), morbidities (including time to first bleeding 
event or hospital admission for bleeding event and first dysphagia-related stent complications or re-intervention), 
and cost-effectiveness. Safety analysis was undertaken in the modified ITT population. The study is registered with 
the International Standard Randomised Controlled Trial registry, ISRCTN12376468, and ClinicalTrials.gov, 
NCT01915693, and is completed.
Findings 220 patients were randomly assigned between Dec 16, 2013, and Aug 24, 2018, from 23 UK centres. The 
modified ITT population (n=199) comprised 102 patients in the usual care group and 97 patients in the EBRT group. 
Radiotherapy did not reduce dysphagia deterioration, which was reported in 36 (49%) of 74 patients receiving usual 
care versus 34 (45%) of 75 receiving EBRT (adjusted odds ratio 0·82 [95% CI 0·40–1·68], p=0·59) in those with 
complete data for the primary endpoint. No significant difference was observed in overall survival: median overall 
survival was 19·7 weeks (95% CI 14·4–27·7) with usual care and 18·9 weeks (14·7–25·6) with EBRT (adjusted hazard 
ratio 1·06 [95% CI 0·78–1·45], p=0·70; n=199). Median time to first bleeding event or hospital admission for a 
bleeding event was 49·0 weeks (95% CI 33·3–not reached) with usual care versus 65·9 weeks (52·7–not reached) 
with EBRT (adjusted subhazard ratio 0·52 [95% CI 0·28–0·97], p=0·038; n=199). No time versus treatment interaction 
was observed for prespecified QoL outcomes. We found no evidence of differences between trial group in time to first 
stent complication or re-intervention event. The most common (grade 3–4) adverse event was fatigue, reported in 
19 (19%) of 102 patients receiving usual care alone and 22 (23%) of 97 receiving EBRT. On cost-utility analysis, EBRT 
was more expensive and less efficacious than usual care.
Interpretation Patients with advanced oesophageal cancer having SEMS insertion for the primary management of 
their dysphagia did not gain additional benefit from concurrent palliative radiotherapy and it should not be routinely 
offered. For a minority of patients clinically considered to be at high risk of tumour bleeding, concurrent palliative 
radiotherapy might reduce bleeding risk and the need for associated interventions.
Funding National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
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Introduction
In the UK, data from 2015–18 showed more than 
9000 new cases of oesophageal cancer and approximately 
8000 deaths due to oesophageal cancer each year. 
Worldwide in 2012, more than 450 000 new cases were 
diagnosed, with greater than 80% of new cases and 
deaths occurring in low-income and middle-income 
nations.1 Most patients present with incurable disease. 
For patients with advanced disease, median survival is 
3–6 months,2 with the majority requiring intervention 
for dysphagia.3,4
Although the ideal intervention for dysphagia palliation 
has not been defined, options include chemical and 
thermal ablation, self-expanding metal stents (SEMS), 
and radiotherapy and chemotherapy alone or in com-
bination. Evidence suggests that in advanced incurable 
oesophageal cancer, SEMS insertion is an appropriate 
intervention for rapid dysphagia relief.5–7 Brachytherapy 
might represent an appropriate alternative8,9 but is rarely 
accessible in UK National Health Service (NHS) settings,10 
and is unavailable in most low-income countries where 
the incidence of advanced oesophageal cancer is highest.1 
Although SEMS is widely implemented for first-line 
management of dysphagia in the UK, the efficacy of 
SEMS alone is limited by early problems with pain, a 
decline in general aspects of quality of life (QoL), and later 
complications such as haemorrhage and tumour over-
growth.5–7 Median time to recurrent dysphagia in stent 
comparator11,12 and brachy therapy studies8 is 11–12 weeks 
and it has profound effects on independence, social 
function, and QoL. Hospitalisation and re-intervention 
account for most stent-related costs,5 imposing a sub-
stantial burden on both NHS resources and a vulner able 
population with a median overall survival of 3–6 months. 
In line with Cochrane review research recommendations,6,7 
com bination of SEMS with other treatments might reduce 
costs and patient burden by reducing adverse events and 
re-interventions at a time when patients are approaching 
the last weeks of life.
The Radiotherapy after Oesophageal Cancer Stenting 
(ROCS) study was developed in response to a UK National 
Institute for Health Research (NIHR) call for research 
proposals into aspects of palliation, and aimed to address 
uncertainties in the evidence base for interventions 
Research in context
Evidence before this study
Before study commencement we searched Medline and the 
Cochrane Database of Systematic Reviews for prospective 
trials of dysphagia palliation interventions published from 
Jan 1, 1995, to Jan 1, 2011, using the terms “dysphagia”, 
“stent”, “oesophageal cancer OR carcinoma”, “radiotherapy” 
and “brachytherapy”. We included randomised controlled trials 
(RCTs), both masked and unmasked, reported in English. 
Studies of interest were those with patients with incurable 
primary squamous cell carcinoma or adenocarcinoma of the 
oesophagus or oesophagogastric junction. We identified a UK 
National Institute for Health Research Health Technology 
Assessment and a Cochrane systematic review confirming the 
efficacy of self-expanding metal stents (SEMS) in relieving 
dysphagia. These studies showed that efficacy of SEMS alone 
was limited by early problems with pain, decline in general 
aspects of quality of life (QoL), and later complications such as 
haemorrhage, tumour overgrowth, and recurrent dysphagia 
within 12 weeks. They called for evidence of interventions in 
combination with a stent to improve outcomes, and evidence 
on QoL and cost-effectiveness. These findings were confirmed 
by a further systematic review during the present study 
period. We identified two studies of brachytherapy versus 
stenting that showed longer dysphagia-free survival and more 
stable health-related QoL with brachytherapy. The literature 
search confirmed low access to brachytherapy for this patient 
group across the UK. A search of ClinicalTrials.gov did not 
reveal any current prospective studies of the more widely 
available palliative external beam radiotherapy (EBRT) in 
combination with stenting for improving dysphagia 
outcomes.
Added value of this study
We believe that the present study is the first sufficiently powered 
RCT to test the efficacy of palliative EBRT in combination with 
stenting for improving dysphagia outcomes in advanced 
oesophageal cancer, and the first RCT to show an effect of EBRT 
on tumour bleeding risk. It also provides prospective data on the 
effect of radiotherapy on re-interventions and service use. 
The addition of radiotherapy after oesophageal stent insertion 
does not reduce dysphagia deterioration and adds significantly to 
the cost of treatment. Reduction of upper gastrointestinal 
bleeding was observed in patients randomly assigned to receive 
radiotherapy after stent insertion, which warrants further 
investigation. This trial provides detailed findings on the poor 
outcomes in this patient group, which are rarely the focus of 
multicentre prospective research.
Implications of all the available evidence
Patients with advanced oesophageal cancer and dysphagia have 
limited treatment options and outcomes are often poor. 
Re-interventions are common following stent insertion. 
This study shows that when stent insertion is required to palliate 
dysphagia, most patients will not additionally benefit from—and 
should not be routinely offered—locoregional radiotherapy. 
Radiotherapy might be reserved for a minority of patients at 
high risk of tumour bleeding, but this strategy should be 
balanced against the burdens of treatment. Our study highlights 
the considerable unmet needs of this patient group. We hope our 
findings will challenge upper gastrointestinal services to establish 
better evidence in this field on other combination therapies and 
how multidisciplinary support can help patients and families 
negotiate symptom burden and improve QoL.
For oesophageal cancer 
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combined with SEMS. External beam radiotherapy 
(EBRT) is rarely used in the UK as a monotherapy for 
rapid dysphagia relief, but its use in the immediate post-
stent period has not been rigorously studied. This study 
addresses the efficacy of adjuvant EBRT compared with 
SEMS alone in reducing the risk of dysphagia 
deterioration, and improving QoL and patterns of service 
use in patients with advanced oesophageal cancer.
Methods
Study design and participants
The ROCS study was designed as a multicentre, parallel-
arm, open-label, phase 3 randomised controlled trial with 
an internal pilot phase examining recruitment. It was 
done in cancer centres and acute care hospitals across 
Scotland, England, and Wales.
A description of the original trial protocol has previously 
been published.13 A summary of changes to the original 
ROCS protocol are provided in the appendix (p 2). The 
final trial protocol is available online. Ethics approval for 
the study was given by the Wales Research Ethics 
Committee 2 in October, 2012 (reference 12/WA/0230).
Participants were patients with incurable oesophageal 
carcinoma (histologically confirmed excluding small 
cell carcinoma; or clinical or radiological evidence of 
invasive tumour and at least high-grade dysplasia of a 
non-small cell type on histology), already referred for a 
stent as primary palliation of dysphagia by members of 
the local upper gastrointestinal multidisciplinary team 
(MDT), age 16 years or older, having an expected 
survival of at least 12 weeks, deemed clinically able by 
the MDT to tolerate radiotherapy, having completed a 
baseline (post-consent) European Organisation for 
Research and Treatment of Cancer (EORTC) quality 
of life questionnaire-oesophagogastric module (QLQ-
OG25),14 unsuitable for radical treatment (oesophagec-
tomy or radical chemoradiotherapy) because of patient 
choice or medical reasons, and with the ability to 
provide written informed consent. We excluded patients 
planned to receive endoscopic treatment of the tumour, 
other than dilatation, in the peri-stent period (except for 
required emergency interventions), those with a 
tumour length of greater than 12 cm (or tumour growth 
within 2 cm of the upper oesophageal sphincter), those 
with presence of a tracheo-oesophageal fistula, or 
pacemaker in the proposed radiotherapy field, those 
who had previous radiotherapy to the area of the 
proposed radiotherapy field, and those who were 
pregnant. Patients in whom brachytherapy or EBRT 
was already planned after stent insertion were not 
included as we were concerned that further addition of 
trial radiotherapy might increase the risk of toxicity. 
The number of such patients was small (brachytherapy 
accounts for <2% of dysphagia inter ventions in the UK 
and EBRT is rarely used for immediate dysphagia relief 
in the UK in the participants of interest10). Patients were 
approached and randomly assigned either before or 
after stent insertion to allow pragmatic accommodation 
within the clinical pathway.
Randomisation and masking
Patients were randomly assigned 1:1 to receive EBRT (plus 
usual care) or usual care alone after stenting by the 
method of minimisation with a random element (80:20) 
via a central telephone randomisation system developed 
by, and based at, the Centre for Trials Research at Cardiff 
University (Cardiff, UK). Minimisation was stratified to 
ensure balanced treatment allocation by a number of 
potential confounding factors: treating centre, stage at 
diagnosis (I–III vs IV), histology (squamous or non-
squamous), and MDT intent to give chemotherapy (yes or 
no). Participants were enrolled and assigned their trial 
group by the local principal investigator or research 
practitioner. The research practitioner was responsible for 
subsequent follow-up data collection. The study was 
necessarily open label and neither the patients nor the 
treating clinicians were blinded to treatment allocation. 
However, classi fication of some events was blinded, 
detailed herein.
Procedures
SEMS insertion was done in the EBRT group and the 
usual care group as per standard procedures at each 
centre. Stent type and length were determined by the 
treating clinician. When possible, the stent length was 
chosen to ensure that at least 2 cm of normal oesophagus 
was covered by the stent above and below the tumour.
Usual care was implemented in both groups according 
to local MDT practice to include, as needed, post-stent 
dietetic advice, referral for palliative and supportive care 
interventions (eg, blood transfusion and supportive 
oncology), and community-based health-care and social-
care follow-up.
In the EBRT group, the study protocol mandated that 
radiotherapy begin within 4 weeks of stent insertion and 
preferably 2 weeks. Treatment dose was prespecified at 
each centre, preferably 20 Gy in five fractions over 1 week 
or, at the treating clinician’s discretion, 30 Gy in ten 
fractions over 2 weeks. Treatment was administered 
according to each centre’s normal radio therapy 
procedures without corrections for inhomo geneity in 
dose calculation. In the event of severe radiotherapy side-
effects or treatment machine unavail ability, gaps in 
treatment of up to 7 calendar days were allowed. If the 
patient missed more than 7 consecutive calendar days 
during radiotherapy treatment, then they were withdrawn 
from the trial and further treatment given at the 
clinician’s discretion. Radiotherapy quality assurance 
was monitored by the NIHR Radiotherapy Trial Quality 
Assurance Group.
Follow-up at home was planned 1 week after stent 
insertion (before any radiotherapy; forming the baseline 
measurement for the primary outcome), and every 4 weeks 
thereafter for up to 1 year (finishing when the last patient 
See Online for appendix
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enrolled had been followed up for 12 weeks). At each 
timepoint, participants completed the EORTC QLQ-OG25, 
EORTC QLQ core 30 (QLQ-C30; version 3.0),15,16 and 
EuroQol 5D questionnaire 3 level (EQ-5D-3L).17,18 Data 
were also collected on WHO performance status, stent 
complications, toxicities (as per the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events [CTCAE] version 4.03), other treatments, and 
health-care and social-care resource use. If a home visit 
was not possible, or if patients preferred, data were 
collected by phone. Additionally, phone calls every 4 weeks 
were introduced midway between home visits to maximise 
capture of the primary outcome data only. Serious adverse 
events were collected in real time via a designated contact 
service from time of informed consent until 60 days after 
stent insertion.
During the pilot phase, an embedded qualitative study 
based on longitudinal interviews explored the feasibility 
of trial recruitment in a subset of patients during 
their first 8 weeks after stent insertion, relating to patient 
experience of the trial and recruitment process, the effect 
of trial interventions on daily life, and the experiences of 
living with advanced oesophageal cancer. 30 longitudinal 
interviews in 15 patients (nine in the EBRT group and 
six in the usual care group) were done in their first 
8 weeks of trial involvement. Interviews were analysed 
with the Braun and Clarke framework for thematic 
analysis.19 Full results of this qualitative study will be 
reported separately.
Outcomes
The primary outcome was deterioration in a dysphagia 
event within 12 weeks after stent insertion, defined as: 
two consecutive deteriorations of more than 11 points 
from baseline20 in patient-reported dysphagia score on 
the EORTC QLQ-OG25, with the first being taken as 
the event timepoint (consecutive deteriorations were 
specified because patients undergoing radiotherapy 
might tem porarily show worsening of dysphagia 
secondary to radiation-induced oesophagitis); one deteri-
oration and no more data possible (patient withdrew 
completely or died before next visit); one deterioration 
and patient missing on the next visit, with patient 
withdrawal or death within 4 weeks of the missed visit; 
additional dysphagia-related primary events consistent 
with the relevant change in dysphagia score (additional 
stent insertion, hospital admission for dysphagia, over-
growth or undergrowth of the stent, grade ≥3 dysphagia 
[CTCAE v4.03], or additional radiotherapy to the 
oesophagus or stent region; assessed and confirmed by 
the chief investigators [DA and AB] as tumour related 
and reviewed by an independent gastro enterologist, all 
masked to treatment group, as a dysphagia-related 
event); or death from any cause. In patients showing 
deterioration at one assessment but with missing data at 
a subsequent assessment, deterioration was timed at the 
previous assessment.
Secondary outcomes were overall survival, QoL 
(including WHO performance status), morbidity (upper 
gastrointestinal-related bleeding event or hospital 
admission for a bleeding event, first dysphagia-
related stent complication, or re-intervention), dysphagia 
deterioration-free survival (DDFS), post-stent  chemo-
therapy or additional radiotherapy, patient experience 
(to be reported in detail elsewhere), and cost effectiveness. 
Overall survival was calculated from the date of stent 
insertion to the date of death from any cause. QoL was 
measured with the EORTC QLQ-C30, EORTC QLQ-OG25, 
and EQ-5D-3L. The prespecified main patient-reported 
outcome items were the global health score from the 
QLQ-C30 and four scales from the EORTC QLQ-OG25: 
odynophagia, pain or discomfort, eating restrictions, and 
eating in front of others. Upper gastrointestinal bleeding 
events were confirmed by the chief investigators who were 
masked to the study group and reviewed by a masked 
independent gastro enter ologist. These events could 
include blood transfusion, haematemesis, other descrip-
tions of upper gastro intestinal haemorrhage or bleeds, or 
interventions related to bleeding (such as argon plasma 
coagulation or additional radiotherapy). If there was no 
clinical evidence that anaemia was due to a bleed then it 
was not considered. Data on treatment with antiplatelet 
drugs, anticoagulants, and nonsteroidal anti-inflammatory 
drugs other than aspirin were collected at each clinical 
assessment visit. Stent complications were defined as re-
stenting, repeat endoscopy, overgrowth or undergrowth of 
the stent, stent blockage, stent fracture, stent slippage, 
and stent-related pain (grade ≥2 on the CTCAE v4.03). 
Dysphagia-related stent events (blindly assessed) only 
influenced the primary outcome if an event had not 
already been identified in the patient-reported OG25 
assessments. Re-interventions (dyphagia-related or not 
related) were defined as additional stent insertion, stent 
removal, endoscopic intervention (including laser therapy 
and alcohol injection), and other palliative radiotherapy 
(including brachytherapy and additional EBRT for 
dysphagia). For monitoring of safety, toxicity was 
measured throughout follow-up with the CTCAE v4.03.
Statistical analysis
Originally the sample size calculation was based on a 
time-to-event analysis for the primary endpoint requiring 
496 participants. However, during the recruitment phase 
of the trial, in view of lower than expected eligible patient 
numbers and substantial missing data after 12 weeks 
reflecting patient deterioration, the independent data 
monitoring committee (IDMC) recommended a revised 
sample size calculation, based on comparison of 
proportions with an event by week 12 rather than a time-
to-event analysis. No early analysis was done that might 
have influenced this recommen dation. To detect a 
reduction in the proportion of patients with deterioration 
from 40% to 20% required 164 patients (82 patients per 
group; 80% power at a two-sided α level of 5%), with a 
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total of 220 to be recruited to allow for 25% loss to follow-
up. This difference in proportions was larger than that for 
the original sample size sought but was in line with the 
difference sought in other studies of stent or non-stent 
interventions for malignant dysphagia.8,21,22 The changes 
were approved by the independent trial steering 
committee and ratified by the funder following further 
independent review.
All statistical analyses followed a predefined statistical 
analysis plan agreed with the IDMC. Our modified 
intention-to-treat (ITT) population was defined as all 
patients who had a stent inserted (otherwise no benefit 
from radiotherapy was expected) and returned a base-
line EORTC QLQ-OG25 (an eligibility criteria). The 
per-protocol (PP) population was defined as the subgroup 
of the modified ITT population that was alive and had 
not withdrawn from trial treatment at 4 weeks after stent 
insertion, and, in the EBRT arm, had received at least 
one fraction of radiotherapy to compare those who could 
have received radiotherapy in the usual care arm with 
those who did in the EBRT arm.
Analysis of the primary binary endpoint of deteri-
oration in dysphagia symptoms by 12 weeks was 
primarily done in the modified ITT population with 
complete case data. Complete cases were defined as 
having complete data for the dysphagia subscale of the 
QLQ-OG25 questionnaire at baseline, week 4, week 8, 
and week 12, or having died with complete data before 
week 12. In the absence of a documented dysphagia-
related event, missing dysphagia scores between two 
non-event dysphagia scores were assumed to be no 
event. Multivariable logistic regression was used to 
adjust for randomisation stratification factors and 
obtain odds ratios (ORs) and 95% CIs for any treatment 
effect in the primary analysis and all sensitivity analyses. 
We did three sensitivity analyses: using the same 
complete case population but treating death by 12 weeks 
without earlier deterioration as no deterioration; 
imputing missing data using a best-case scenario that 
assumed no deterioration in a missing QLQ-OG25 form 
immediately before an QLQ-OG25 form that showed 
deterioration (or a dysphagia-related primary event), or 
that assumed no deterioration in a missing QLQ-OG25 
form immediately before death; and imputing missing 
data using a worst-case scenario that assumed dete-
rioration in a missing QLQ-OG25 form immediately 
before an QLQ-OG25 form that showed deterioration 
(or a dysphagia-related primary event), or that assumed 
deterioration in a missing QLQ-OG25 form immediately 
before death. As further sensitivity analyses, all 
analyses were repeated in the PP population. 
As a secondary endpoint per IDMC guidance, DDFS 
was calculated in the ITT population from the date of 
stent insertion to the date of deterioration in dysphagia 
(as per the primary outcome definition). We analysed 
overall survival and DDFS using Kaplan-Meier plots and 
Cox regression (with the usual care group as the 
reference for the treatment effect measured by hazard 
ratios [HRs] and 95% CIs), with patients without events 
being censored at the time of last contact and adjusted 
for randomisation stratification factors with treating 
centre included as a shared frailty. We tested the model 
fit and assumptions using Cox-Snell residuals and 
Schoenfeld’s global test.
QoL data and WHO performance status scores, 
prespecified in the statistical analysis plan, were 
analysed by the same method: the distributions of the 
variables were tested for normality with the Shapiro-
Wilk test, kernel density, normal probability, and 
normal quantile plots, and either mean scores (or 
median scores if the was evidence of non-normality) 
Figure 1: Inclusion of patients receiving a stent for primary palliation of dysphagia
ITT=intention-to-treat. QLQ-OG25=quality of life questionnaire-oesophagogastric module. PP=per-protocol. 
*Research staff unavailable. †The number of weeks before radiotherapy should have been started. ‡Two patients 
withdrawn due to patient choice; one patient uncontactable; and one patient relocated. §Seven patients 
withdrawn due to patient choice; and one at clinician request.
112 assigned to usual care alone 
102 in the modified ITT population
220 randomly assigned
1252 patients assessed for eligibility
1032 excluded
706 not eligible
113 with previous radiotherapy to proposed field
38 not expected to survive 12 weeks
22 with ineligible histology
100 with other clinical reasons
200 had received other treatments 
51 unable to provide consent
182 without reason given
326 eligible
208 declined participation
29 due to clinician choice
4 at sites with enrolment or randomisation issues*
10 entered another study
3 died
72 without reason given
90 in the PP population
10 excluded from modified ITT analysis
2 without stent insertion
8 without a baseline QLQ-OG25
assessment
12 excluded from PP analysis
8 died within 4 weeks after stent 
insertion†
4 withdrawn from the trial within
4 weeks after stent insertion†‡
108 assigned to external beam radiotherapy (plus
usual care)
97 in the modified ITT population
82 in the PP population
11 excluded from modified ITT analysis
3 without stent insertion
8 without a baseline QLQ-OG25
assessment
15 excluded from PP analysis
7 died before radiotherapy
8 withdrawn from the trial before
radiotherapy§
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plotted accordingly. Box plots were used to show the 
median, IQR, upper and lower adjacent values, and any 
outliers (per STATA 16 procedures) as dots, at each 
timepoint. Mean values were plotted with 95% CIs 
against time. Linear mixed models were used to 
compare differences between trial groups for each 
subscale or single item on the EORTC QLQ-C30, 
EORTC QLQ-OG25, and WHO performance status. We 
included time as a categorical covariate using the week 
of observation from week 1 to week 16, after which the 
proportion of missing data became too high (>30% of 
randomly assigned patients returning questionnaires). 
If an intermediate value was missing, the corresponding 
time was skipped. Covariates included trial group, age, 
time 0 score, and randomisation stratification factors. 
The mixed model residuals were tested for normality.
Time to first morbidity event was compared between 
trial groups by competing risks regression (used to 
calculate subhazard ratios and 95% CIs), with death as a 
competing risk, adjusted for randomisation stratification 
factors, and with cumulative incidence functions plotted 
by trial group and median time to event calculated with the 
stci command in STATA. Treatment-emergent grade 3–4 
toxicity was reported in the modified ITT population. Risk 
ratios were calculated in a post-hoc analysis to compare 
rates of toxicities and post-stent chemotherapy  or additional 
radiotherapy between treatment arms.
We assessed cost-effectiveness from a UK NHS and 
Personal Social Services perspective using a combined 
decision tree and Markov model (appendix p 33), 
comparing the costs of usual care alone to EBRT over a 
time horizon of 12 weeks after stent insertion (extended 
to 12 months in a sensitivity analysis). We considered the 
intervention implementation costs of EBRT and the cost 






Before stent insertion 39 (38%) 36 (37%)
After stent insertion 63 (62%) 61 (63%)
Age, years 73·5 (65·4–81·5); 102 72·0 (65·3–79·9); 97
WHO performance status
0 10 (10%) 10 (10%)
1 61 (60%) 59 (61%)
2 27 (26%) 27 (28%)
3 4 (4%) 1 (1%)
Tumour type
Adenocarcinoma 68 (67%) 61 (63%)
Squamous 33 (32%) 34 (35%)
Undifferentiated or 
other
1 (1%) 2 (2%)
Overall length of primary tumour (endoscopic assessment)*
Measured length, cm 5·0 (4·0–7·0); 64 6·0 (4·0–8·0); 57
Estimated length, cm 6·0 (4·5–8·0); 28 7·0 (5·0–8·0); 33
Measured or estimated 
length, cm
5·9 (4·0–7·0); 92 6·0 (4·5–8·0); 90
Missing 10 (10%) 7 (7%)
Alternative method for assessing length*
PET 5 (5%) 7 (7%)
CT 23 (23%) 23 (24%)
Missing 0 3 (3%)
Site of predominant tumour
Upper oesophagus 3 (3%) 3 (3%)
Middle oesophagus 24 (24%) 25 (26%)
Lower oesophagus 75 (74%) 68 (70%)
If lower oesophagus: 
involvement of GOJ
38 (37%) 38 (39%)
Unknown 0 1 (1%)
Extension across GOJ (if involvement of GOJ)
Siewert type 1 21 (21%) 20 (21%)
Siewert type 2 15 (15%) 13 (13%)
Missing 2 (2%) 5 (5%)
(Table 1 continues in next column)





(Continued from previous column)
T stage†
0 1 (1%) 0
1 1 (1%) 1 (1%)
2 4 (4%) 7 (7%)
3 61 (60%) 54 (56%)
4 29 (28%) 31 (32%)
Missing 6 (6%) 4 (4%)
N stage†
0 17 (17%) 10 (10%)
1 46 (45%) 46 (47%)
2 20 (20%) 20 (21%)
3 15 (15%) 17 (18%)
Missing 4 (4%) 4 (4%)
M stage†
0 46 (45%) 41 (42%)
1 49 (48%) 50 (52%)
Missing 7 (7%) 6 (6%)
Overall stage†
I–III 51 (50%) 46 (47%)
IV 51 (50%) 51 (53%)
Previous chemotherapy given‡
No 87 (85%) 74 (76%)
Yes 15 (15%) 23 (24%)
Chemotherapy intended after stent insertion
Yes 36 (35%) 34 (35%)
No 66 (65%) 63 (65%)
EQ-5D-3L index scores 0·648 (0·226); 102 0·578 (0·297); 97
Data are n (%), median (IQR); n, or mean (SD); n. ITT=intention to treat. 
GOJ=gastric-oesophageal junction. EQ5D=EuroQol-5D-3L. *In addition to 
endoscopic assessment in some patients. †At diagnosis. ‡Details of therapies 
provided in the appendix p 20. 
Table 1: Baseline demographic and clinical characteristics in the 
modified ITT population
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of subsequent health and social care resource use 
(primary, secondary, hospice, and social care including 
any cancer treatment and medications received). Health 
and social care resource use was captured with a Client 
Service Receipt Inventory. As the analysis was less than 
12 months, discounting was not applied. The model 
calculated the incremental cost per quality-adjusted life-
year (QALY) gained based on dysphagia data, health-care 
resource use, and health utilities derived from the 
EQ-5D-3L responses collected at the follow-up points every 
4 weeks and the UK EQ-5D value set.23 Costs were applied 
by calculating number of patients in each stage of the 
model and multiplying by mean cost for that stage. In the 
base-case analysis, patient-level data was used to populate 
the model with the first 12 weeks of data. The health-care 
costs in primary, secondary and social care for both EBRT 
and control groups post-randomisation were summated 
and mean absolute cost difference per patient (including 
95% CIs and p values) were calculated with SPSS 
(version 26). Independent sample t-tests were used for 
comparisons with a 5% significance level. For the 
12-month time horizon, the model structure remained the 
same. However, costs, utilities, and transition probabilities 
between the health states of stable or worsening dysphagia 
were updated to include the data from 13–52 weeks. 
Where data were missing, mean patient-level interpolation 
was used. 
Sensitivity analyses were undertaken to test the 
robustness of the cost utility analysis considering the 
uncertainty in input parameters such as costs and 
outcomes and in different scenarios. In a deterministic, 
univariate sensitivity analysis, we changed intervention 
and health-care costs and outcomes individually within 
plausible ranges (using 10%, 20%, and 30% of the mean 
value). Scenario analyses were used to test different 
assumptions and recalculate the incremental cost per 
QALY gained (eg, based on different populations: 
complete cases and all available cases). The time horizon 
was also extended to 12 months to explore longer term 
effects of the intervention. In a probabilistic sensitivity 
analysis, we used non-parametric bootstrapping to address 
joint parameter uncertainty and assess the effect on the 
incremental cost during 1000 simulations, undertaken 
with random sampling from distributions of costs and 
outcomes (with replacement).
Detailed statistical methods are presented in the 
protocol.13 In all analyses, a p value of less than 0·05 was 
considered to indicate significance. All statistical 
analyses were done with STATA 16. This study is 
registered as an International Standard Randomised 
Controlled Trial, ISRCTN12376468, and with 
ClinicalTrials.gov, NCT01915693.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
1252 patients were screened, 546 were found to be 
eligible, and 220 were enrolled and randomly assigned at 
23 hospital sites (appendix p 21) between Dec 16, 2013, 
and Aug 24, 2018. Of these patients, 112 were allocated to 
receive usual care alone and 108 to receive adjuvant 
EBRT (plus usual care) after stent insertion (figure 1). 
The modified ITT population comprised 102 patients in 
the usual care group and 97 in the EBRT group. Unless 
otherwise stated, all results described herein are for the 
modified ITT population. Baseline characteristics are 
shown in table 1 and details of stents used are given in 
the appendix (p 3). The randomisation stratification 
factors of tumour histology, stage at diagnosis, and 
intended chemotherapy after stent insertion (and treating 
centre [data not shown]) were well balanced between trial 
groups as were other baseline characteristics.
Compliance with radiotherapy is shown in the 
appendix (p 4) for patients assigned to EBRT. Of the 










Incomplete case data at week 12
Withdrawn from the trial before 
week 12 with no event
6 (6%) 5 (5%) NA ··
Died before week 12 with incomplete 
data and no event†
8 (8%) 6 (6%) NA ··
Alive at week 12 with incomplete data 
and no event†
14 (14%) 11 (11%) NA ··
Reasons for trial withdrawal
Participant choice 3 (3%) 4 (4%) NA ··
On family’s behalf via clinical nurse 
specialist
1 (1%) 0 NA ··
Loss to follow-up 1 (1%) 1 (1%) NA ··
Relocated 1 (1%) 0 NA ··
Complete case data at week 12
Total with complete data 74 (73%) 75 (77%) NA ··
Died with complete data 20 (20%) 22 (23%) NA ··
Alive at week 12 with complete data 54 (53%) 53 (55%) NA ··
Primary analysis: complete case data (death without earlier deterioration as an event)
Number of primary events or deaths 36/74 (49%) 34/75 (45%) 0·82 (0·40–1·68) 0·59
Sensitivity analysis: complete case data (death without earlier deterioration as non-event)
Number of primary events 21/74 (28%) 21/75 (28%) 1·05 (0·49–2·25) 0·89
Sensitivity analysis: best-case scenario
Total with complete data 90 (88%) 88 (91%) NA ··
Number of primary events or deaths 40/90 (44%) 36/88 (41%) 0·85 (0·44–1·62) 0·61
Sensitivity analysis: worst-case scenario
Total with complete data 90 (88%) 88 (91%) NA ··
Number of primary events or deaths 53/90 (59%) 46 (52%) 0·73 (0·38–1·40) 0·35
Data are n (%) unless otherwise specified. NA=not applicable. *Adjusted for randomisation stratification factors. 
†Missing at least one assessment at week 4, week 8, or week 12 and unable to impute a non-deterioration between 
two adjacent non-deteriorations.
Table 2: Patient status and primary endpoint analyses at 12 weeks after stent insertion in the modified 
ITT population
For the Client Service Receipt 
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withdrawn from the trial before radiotherapy treatment 
was given (figure 1). One (1%) participant chose a 
reduction in the planned radiotherapy from 30 Gy in 
ten fractions to 15 Gy in five fractions. All remaining 
participants received the protocol radiotherapy except 
one (1%) participant who received 8 Gy in one dose as this 
was the local practice (classified by the trial management 
group [AB, DA, JB, GG, AN, LN, MS, JF, ST, AM, JS, TC, 
and DF] as a minor deviation as an appropriate palliative 
dose; and patient retained in the PP population).
Of the modified ITT population, 74 patients in the usual 
care group versus 75 patients in the EBRT group had 
complete data at week 12 for the primary endpoint (table 2). 
The baseline characteristics of patients with and without 
complete data were well balanced (appendix p 6). Our 
primary analysis of complete case data showed no signifi-
cant difference in the proportion of patients with a 
dysphagia deterioration event up to 12 weeks after stent 
insertion between the groups (36 [49%] of 74 patients vs 
34 [45%] of 75 patients; adjusted OR 0·82 [95% CI 
0·40–1·68], p=0·59). The sensitivity analyses treating 
death as no event, imputing missing data under best-case 
and worse-case scenarios (table 1), and in the PP population 
(appendix p 8) consistently found no signifi cant difference.
Analysis of DDFS showed median time to a dysphagia 
event or death was 13·1 weeks (95% CI 10·0–17·9) in 
the usual care group and 14·7 weeks (12·1–17·4) in the 
EBRT group (adjusted HR 0·92 [95% CI 0·68–1·26], 
p=0·62; figure 2A). We also observed no significant 
difference in overall survival. Median overall survival 
was 19·7 weeks (95% CI 14·4–27·7) in the usual care 
group versus 18·9 weeks (14·7–25·6) in the EBRT group 
(adjusted HR 1·06 [95% CI 0·78–1·45], p=0·70; 
figure 2B). Median follow-up in patients alive at the last 
date of recorded follow-up (Dec 20, 2018) was 22·9 weeks 
(95% CI 4·0–41·9; n=16) in those receiving usual care 
versus 22·1 weeks (8·0–34·7; n=15) in those receiving 
EBRT. The last date of follow-up was March 6, 2019. 
Total deaths from all causes are summarised in the 
appendix (p 9).
For EORTC QLQ-C30 and EORTC QLQ-OG25 
responses, the proportion of missing data at each time-
point (including withdrawals, deaths, and loss to follow-
up) was balanced across trial groups and increased 
from 0–1% at the first post-stent assessment to 23–25% at 
week 4, 36–41% at week 8, 49–59% at week 12, and 59–65% 
at week 16 (appendix pp 10–11). The appendix (pp 12–17) 
shows the results of the linear mixed models for the 
EORTC QLQ-C30 and QLQ-OG25 questionnaire scales 
and WHO performance status. The prespecified main 
subscales or items of interest were global health 
(QLQ-C30; appendix p 22), odynophagia (appendix p 22), 
pain or discomfort (appendix p 23), eating restrictions 
(appendix p 23), and eating in front of others 
(appendix p 24; all QLQ-OG25). We found no evidence of 
a time versus treatment interaction in any of these items 
(p values >0·05; appendix pp 12–13).
Evidence of a time versus treatment interaction was 
observed for dysphagia (p=0·013; appendix p 12). The 
median dysphagia scores were higher (ie, worse 
swallowing problems and more severe dysphagia) at 
week 4 in the EBRT group than in the usual care group, 
but the same by week 8 (appendix p 24). This short-term 
deterioration was expected, hence the requirement for 
two successive deteriorations in the definition of the 
primary endpoint. We also found evidence of a time 
versus treatment interaction for pain measured by the 
EORTC QLQ-C30 (p=0·005; appendix p 14). Median pain 
score was higher at weeks 8, 12, and 16 in the EBRT group 
(appendix p 25). Furthermore, we observed a time versus 
treatment interaction for constipation (p=0·009; appendix 
p 14). The mean score was higher at weeks 8, 12, and 16 in 
the EBRT group, mirroring the pain scales and possibly 
related to greater use of analgesia. We also observed 
significant time–treatment interactions for trouble 
swallowing saliva, anxiety, body image, and cognitive 
functioning. We found no evidence of time–treatment 
Figure 2: Dysphagia deterioration-free survival (A) and overall survival (B) by trial group up to 1 year
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treatment interactions for any other QoL scales or WHO 
performance status (appendix pp 12–17, 25–26).
Median time to first upper gastrointestinal-related 
bleeding or hospital admission for a bleeding event was 
longer with EBRT than with usual care (65·9 weeks 
[52·7–not reached] vs 49·0 weeks [95% CI 33·3–not 
reached]; adjusted subhazard ratio 0·52 [95% CI 
0·28–0·97], p=0·038; appendix p 26). Table 3 shows the 
analysis of upper gastrointestinal-related bleeding events 
by trial group, for the total study period and up to 
week 16. Blood transfusion was the most common event, 
followed by haematemesis and upper gastrointestinal 
haemorrhage or bleed.
We found no evidence of differences between trial 
groups in time to first dysphagia-related stent 
complication or re-intervention event (appendix p 27), 
including additional stent insertion (appendix p 28), 
repeat endo scopy (appendix p 29), overgrowth or under-
growth of the stent (appendix p 30), or stent-related pain 
(appendix p 31).
Table 4 shows the proportions of patients with 
treatment-emergent grade 3–4 toxicities by trial group 
between week 0 and week 16. The most common 
grade 3–4 adverse event was fatigue, reported in 19 (19%) 
of 102 patients receiving usual care alone and 22 (23%) of 
97 receiving EBRT. RRs were calculated (not shown) for 
each toxicity in a post-hoc analysis, and all of the 95% CIs 
included 1, but we noted that the point estimates of the 
RRs were greater than 2 (indicating increased adverse 
events in the EBRT group) for vomiting and abdominal 
pain. However, the absolute numbers of patients with 
abdominal pain were low in both groups (table 3). Three 
deaths (two in the usual care group, one due to a fall 
[eventually categorised as hospital-acquired pneumonia 
after admission for the fall] and one due to myocardial 
infarction; and one in the EBRT group due to multifocal 
ischaemic stroke) were reported via the real-time serious 
adverse event system (appendix p 9), none of which were 
considered to be related to treatment.
Additional palliative radiotherapy was received by 
20 (20%) of 102 patients in the usual care group and 








Number of patients with ≥1 event 29 (28%) 16 (16%)
Number of patients with each type of event
Blood transfusion 26 (25%) 13 (13%)
Haematemesis 5 (5%) 6 (6%)
Upper gastrointestinal haemorrhage or 
bleed
8 (8%) 2 (2%)
Melaena 4 (4%) 0
Argon plasma coagulation due to bleed 0 1 (1%)
Additional radiotherapy due to bleed 1 (1%) 0
Anaemia due to bleed 4 (4%) 2 (2%)
Number of patients with ≥1 event who 
received antiplatelet drugs*
0 0
Number of patients with ≥1 event who 
received anticoagulants†
7 (7%) 7 (7%)
Number of patients with ≥1 event who 
received NSAIDs‡ other than aspirin
4 (4%) 0
Up to week 16 after stent insertion
Number of patients with ≥1 event 19 (19%) 10 (10%)
Number of patients with each type of event
Blood transfusion 13 (13%) 9 (9%)
Haematemesis 4 (4%) 3 (3%)
Upper gastrointestinal haemorrhage or 
bleed
6 (6%) 1 (1%)
Melaena 3 (3%) 0
Argon plasma coagulation due to bleed 0 0
Additional radiotherapy due to bleed 0 0
Anaemia due to bleed 2 (2%) 2 (2%)
Number of patients with ≥1 event who 
received antiplatelet drugs*
0 0
Number of patients with ≥1 event who 
received anticoagulants†
5 (5%) 4 (4%)
Number of patients with ≥1 event who 
received NSAIDs‡ other than aspirin
2 (2%) 0
Data are n (%). NSAID=non-steroidal anti-inflammatory drug. *Aspirin or 
clopidogrel. †Dalteparin, enoxaparin, rivaroxaban, or other unspecified 
anticoagulant. ‡NSAID type not reported separately.







Fatigue 19 (19%) 22 (23%)
Dysphagia 11 (11%) 9 (9%)
Anaemia 10 (10%) 6 (6%)
Anorexia 7 (7%) 9 (9%)
Stent-related pain 6 (6%) 8 (8%)
Nausea 5 (5%) 7 (7%)
Vomiting 4 (4%) 11 (11%)
Upper gastrointestinal 
haemorrhage
4 (4%) 2 (2%)
Thromboembolic event 3 (3%) 4 (4%)
Bronchopulmonary infection 3 (3%) 3 (3%)
Abdominal pain 2 (2%) 5 (5%)
Oesophageal reflux 2 (2%) 1 (1%)
Dyspepsia 2 (2%) 1 (1%)
Oesophagitis 2 (2%) 0
Abdominal distension 1 (1%) 1 (1%)
Mucositis 1 (1%) 1 (1%)
Fever 1 (1%) 0
Gastritis 1 (1%) 0
Aspiration 0 2 (2%)
Oesophageal fistula 0 1 (1%)*
Data are n (%). *Detected after stent insertion and participant retained in all 
analyses.
Table 4: Participants with grade 3–4 toxicity at weeks 0–16 after stent 
insertion
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0·23–0·99], p=0·039; appendix p 18). In the usual care 
group, 16 (80%) of 20 patients received radiotherapy to 
the oesophagus, compared with two (22%) of the nine 
patients in the EBRT group (RR 0·28 [0·08–0·96], 
p=0·0030). Median dose and fractions were 20 Gy in five 
fractions in the usual care arm and 8 Gy in one fraction 
in the EBRT group.
The MDT intended to give chemotherapy after stent 
insertion to 36 (35%) of 102 patients in the usual care 
group and 34 (35%) of 97 patients in the EBRT group 
(table 1). Among these patients, 29 (81%) in the usual care 
group were given chemotherapy, whereas, less than half 
(15 [44%]) in the EBRT group were given chemotherapy 
(RR 0·55 [95% CI 0·36–0·83], p=0·0016; appendix p 19).
In our qualitative study, participants in the EBRT group 
described whether potential benefits of radiotherapy 
were worthwhile against additional burdens of hospital 
attendance and of pain and fatigue. Participants from 
both study groups revealed ongoing challenges with 
eating despite stent placement. They suggested that the 
technical intervention of stenting does not address 
physical and social eating concerns and symptoms. 
Information around diet, symptom control, and general 
medical management throughout the course of the 
disease was often scarce. Full results of this quantitative 
analysis will be reported elsewhere.
The costs of health-care and social-care service use in 
the 12 weeks after stent insertion for the usual care and 
EBRT groups are reported in table 5 and the appendix 
(p 32). No significant differences were found in care 
settings, medication costs, or total care costs (excluding 
EBRT cost) per patient between groups. Mean EBRT 
intervention cost was £1297·34 (SD 296·38) per patient, 
which explained the significant difference in total mean 
cost (including EBRT cost), of £1831·77 (95% CI 
387·43–3276·11, p=0·013) favouring usual care. The base-
case cost-utility analysis (12-week time horizon) showed 
that EBRT was more costly and had lower efficacy than 
stent only, and thus was not a cost-effective treatment at a 
willingness-to-pay threshold of £20 000 per QALY gained 
(appendix p 19). This conclusion did not change when the 
time horizon was extended to 12 months and when 
parameters for cost and outcomes were varied in 
sensitivity analyses (appendix p 20).
Discussion
Our results show that palliative radiotherapy does not 
reduce the proportion of patients with recurrent 
dysphagia at 12 weeks, nor does it improve overall 
survival or reduce service use. The addition of radio-
therapy to stent insertion in advanced oesophageal 
cancer is therefore not routinely recommended. Patients 
in the radiotherapy group did have significantly fewer 
bleeding events, an effect which persisted and increased 
with time. From a clinical perspective, these findings 
suggest that radio therapy could be considered for 
patients deemed at increased risk of bleeding rather than 
for all patients, to minimise treatment burden.
ROCS was designed to address gaps in the evidence on 
improving dysphagia outcomes and NHS and personal 
burdens in patients with advanced oesophageal cancer,5–7 
with use of a widely available intervention (EBRT) 
combined with stenting. The choice to assess palliative 
stent therapy was intended to reflect real-world UK 
practice, where SEMS is the predominant option for 
rapid dysphagia relief in advanced oesophageal cancer, 
accounting for more than 90% of endoscopic and 
radiological interventions.10 ROCS’ target population 
therefore excluded patients with non-severe dysphagia 
being considered for inter ventions other than a stent, and 
those too unwell to have a stent. Although intra luminal 
brachytherapy might be considered an appropriate 
alternative to stenting particularly in patients with longer 
term survival prospects,7–9 few services in the UK have 
access to brachytherapy, and it accounts for less than 2% 
of dysphagia interventions in the NHS.10 Similarly, 
incorporation of endoluminal radiotherapy with a stent as 
a single modality has been shown to lower dysphagia 
scores with time compared with a stent alone,24 but again, 
the equipment and expertise is not widely available and 
Usual care group (n=102) External beam radiotherapy 
group (n=97)
Absolute difference (95% CI) p value
EBRT cost NA £1297·34 (296·38) ·· ··
Primary care £312·01 (410·02) £310·65 (400·09) –1·36 (-114·69 to 111·97) 0·98
Secondary care £3756·21 (4410·26) £4018·96 (5000·51) 262·75 (–1053·76 to 1579·26) 0·69
Hospice care £193·67 (746·57) £150·86 (605·37) –42·80 (–233·39 to 147·78) 0·66
Social care* £195·61 (621·18) £535·17 (1552·36) 339·57 (11·95 to 667·19) 0·042†
Medication £210·24 (183·42) £186·52 (186·82) –23·72 (–75·49 to 28·04) 0·37
Total cost
Total cost including EBRT £4667·73 (4719·99) £6499·50 (5,593·65) 1831·77 (387·43 to 3276·11) 0·013
Total cost excluding EBRT £4667·73 (4719·99) £5202·16 (5613·63) 534·43 (–912·86 to 1981·73) 0·47
Costs per patient are summarised as mean (SD). *Visits at home by community nurses or care assistants (eg, to help with personal care). †This result was no longer 
statistically significant after Bonferroni-Holm correction for multiple comparisons of total care costs.
Table 5: Cost of care resources used per patient in the 12 weeks after randomisation in the modified ITT population
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cost is likely to be substantially higher.25 By contrast, 
palliative EBRT is widely available across the UK, and at 
lower cost. The prespecified dose in this study, 20 Gy in 
five fractions, reflected the most widely used palliative 
dose used across the UK at the time of study design,26 
with the 30 Gy in ten fractions dose available if 
prespecified by the treating clinician. The timing of the 
primary endpoint at 12 weeks reflects the mean stent 
patency reported by Homs and colleagues8 and other 
studies,11,12 and the median overall survival of around 
19 weeks in both groups confirms that our participant 
population accurately reflects the wider clinical popu-
lation.2 The finding that almost twice as many patients in 
the control group received their preplanned chemotherapy 
is noteworthy. This might reflect treatment burden in the 
radiotherapy group discouraging planned chemotherapy 
uptake, or could reflect participant or clinician assessment 
that an active treatment had already been given in the 
form of radiotherapy.
Exploration of patient experiences in our qualitative 
study addressed previous gaps in understanding patient 
and family experiences of advanced oesophageal cancer5 
and QoL trade-offs.27 The results reflect the challenges of 
their lived experiences of eating restrictions, concerns 
over nutrition and diet, and a trial and error approach to 
combating these. These resonate with other findings28 
and emphasise the need for more structured, proactive 
multidisciplinary approaches in patients receiving 
palliative stent therapy.27
Although to our knowledge, this study is the first of its 
kind and has been completed in a patient group with a 
poor prognosis, it does have some limitations. Originally 
the sample size calculation was based on a time-to-event 
analysis for the primary endpoint requiring 496 partici -
pants. Due to recruitment and data capture challenges 
associated with the poor prognosis of the study population, 
this approach was revised during the study, on advice 
of the IDMC, to a sample size calculation based on 
comparison of patient proportions with an event by 
week 12. Although the revised primary outcome might 
have affected the ability of the study to detect a true effect 
for EBRT, the consistency of the results across sensitivity 
analyses is robust, including the secondary analysis of 
DDFS. Whether death was treated as an event or not did 
not alter the primary outcome. In pragmatically allowing 
two radiotherapy schedules in the EBRT group, we did not 
aim to seek a difference between doses and the small 
number of patients receiving 30 Gy precludes any such 
analysis (64 [78%] of 97 received 20 Gy in five fractions). We 
also acknowledge the large number of QoL secondary 
endpoints assessed in this study and associated issues that 
arise with multiple comparisons, hence we urge caution 
in the overinterpretation of significant findings found 
amongst them. Finally, this study was inevitably open-label 
and some outcome measures could be prone to assessment 
bias, particularly the adverse events known to be side-
effects of radiation. We attempted to mitigate this bias with 
the use of a comprehensive panel of secondary outcome 
measures and use of masked assessors to review bleeding 
events. The baseline QoL assessments (week 1 post-stent) 
were done after randomisation (and therefore might have 
been suscep tible to bias), but we noted that most scores 
were balanced between groups at that timepoint.
In summary, the ROCS study confirms that patients 
with advanced oesophageal cancer requiring a stent to 
improve dysphagia will not benefit further from the 
addition of concurrent palliative radiotherapy. In addition, 
the study provides detailed data on the poor outcomes in 
these patients, which are rarely the focus of multicentre 
prospective research. For patients with a long-term 
prognosis and considered to have a markedly increased 
risk of tumour bleeding, concurrent palliative radio-
therapy might reduce bleeding risk and the need for 
associated interventions. Future research should focus on 
alternative, readily accessible interventions that might be 
effectively combined with stenting or compared as a 
monotherapy, and effective, multidisciplinary, supportive 
interventions that address the multidimensional concerns 
around eating and nutritional intake.
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providing sufficient detail to uniquely identify the dataset sought and 
appropriate contact details for the requestor.
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